HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Felipe Melo Cruz Selected Research

BEVZ92

12/2018Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Felipe Melo Cruz Research Topics

Disease

1Sudden Death
12/2018
1Intestinal Obstruction (Obstruction, Intestinal)
12/2018
1Intestinal Perforation
12/2018
1Neutropenia
12/2018
1Colorectal Neoplasms (Colorectal Cancer)
12/2018

Drug/Important Bio-Agent (IBA)

1BEVZ92IBA
12/2018
1Bevacizumab (Avastin)FDA Link
12/2018
1Biosimilar PharmaceuticalsIBA
12/2018

Therapy/Procedure

1Drug Therapy (Chemotherapy)
12/2018